Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | TGM2 | P21980 | 1/20 | 0.63 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.62 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.62 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | CPB1 | P15086 | 1/20 | 0.55 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.55 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.54 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | ANPEP | P15144 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL616935 | 0.98 | HTT (0.70) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL335088 | 0.95 | HTT (0.70) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL23728768 | 0.94 | HTT (0.65) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL22356684 | 0.94 | HTT (0.65) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL19240717 | 0.94 | HTT (0.68) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| Bicarbonate SCHEMBL10633260 | 0.94 | HTT (0.68) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL7863455 | 0.94 | HTT (0.68) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL4363476 | 0.94 | HTT (0.68) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL235394 | 0.94 | HTT (0.68) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL3049211 | 0.94 | HTT (0.68) | HTTLMNASMN1; SMN2TGM2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112279835-A | Aromatic ring or aromatic heterocyclic imidazole compound, preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2021-01-29 | — | — | CN | claimed |
| US-5602161-A | ELASTASE INHIBITORS; PREVENTING AND TREATING EMPHYSEMA, ENDOTOXIN-INDUCED LUNG DISORDERS | WAKAMOTO PHARMACEUTICAL CO., LTD. (JP) | 1997-02-11 | — | — | US | claimed |
| EP-0676396-A1 | Tetrazolylphenyl pivalate derivatives and medicinal composition containing the same as effective component | Wakamoto Pharmaceutical Co., Ltd. (JP) | 1995-10-11 | — | — | EP | claimed |
| US-12545636-B2 | Acyclic lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4662209-A1 | CONJUGATE COMPOUNDS AND COMPOSITIONS | Rezubio Pharmaceuticals Co., Ltd (CN) | 2025-12-17 | — | — | EP | disclosed |
| US-20250228777-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2025-07-17 | — | — | US | disclosed |
| US-12312293-B2 | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20250115561-A1 | BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-12263248-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20250073338-A1 | CONJUGATE COMPOUNDS AND COMPOSITIONS | REZUBIO PHARMACEUTICALS CO., LTD (CN) | 2025-03-06 | — | — | US | disclosed |
| WO-2025016294-A1 | RNAI AGENT FOR INHIBITING EXPRESSION OF KETOHEXOKINASE AND USE THEREOF | 云合智药（苏州）生物科技有限公司 | 2025-01-23 | — | — | WO | disclosed |
| EP-0496561-A2 | [[(2-Amino-3,4-dioxo-1-cyclobuten-1-yl)amino]alkyl]-acid derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-07-29 | — | — | EP | disclosed |
| US-5126448-A | Anxiolytic agents, learning enhancement | ASAHI KASEI KOGYO K.K. (JP) | 1992-06-30 | — | — | US | disclosed |
| WO-1992003429-A1 | RENIN INHIBITORS | ABBOTT LABORATORIES (US) | 1992-03-05 | — | — | WO | disclosed |
| EP-0285671-A1 | PYRIDINE DERIVATIVES | Asahi Kasei Kabushiki Kaisha (JP) | 1988-10-12 | — | — | EP | disclosed |
| EP-0074787-B1 | RENALLY ACTIVE DIPEPTIDES | SMITHKLINE BECKMAN CORPORATION (US) | 1985-03-27 | — | — | EP | disclosed |
| US-4448972-A | Adamantyl containing intermediates | SMITHKLINE BECKMAN CORPORATION (US) | 1984-05-15 | — | — | US | disclosed |
| US-4395401-A | Renally active dipeptides | SMITHKLINE BECKMAN CORPORATION (US) | 1983-07-26 | — | — | US | disclosed |
| US-4387049-A | Adamantyl containing peptides | SMITHKLINE BECKMAN CORPORATION (US) | 1983-06-07 | — | — | US | disclosed |
| EP-0074787-A1 | Renally active dipeptides | SMITHKLINE BECKMAN CORPORATION (US) | 1983-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115561-A1 | BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | CFTR, SCNN1B, SCNN1G | HTT 1451/4885LMNA 1712/4885SMN1; SMN2 1826/4885 |
| US-12312293-B2 | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents | PLTP, LNPK, PLIN3 | HTT 2538/4885LMNA 712/4885SMN1; SMN2 1663/4885 |
| US-12545636-B2 | Acyclic lipids and methods of use thereof | PLTP, LNPEP, PCTP | HTT 2716/4885LMNA 458/4885SMN1; SMN2 1172/4885 |
| US-12263248-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | LNPK, PLTP, PLIN3 | HTT 2525/4885LMNA 1539/4885SMN1; SMN2 2883/4885 |
| US-20250073338-A1 | CONJUGATE COMPOUNDS AND COMPOSITIONS | GPR119, GPR65, GPR55 | HTT 3666/4885LMNA 3609/4885SMN1; SMN2 3045/4885 |
| US-20250228777-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | HTT 2525/4885LMNA 1539/4885SMN1; SMN2 2883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.